DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
DaShenLin Pharmaceutical Group Co Ltd
Total Equity
DaShenLin Pharmaceutical Group Co Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
|
Total Equity
¥7.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
LBX Pharmacy Chain JSC
SSE:603883
|
Total Equity
¥6.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
12%
|
|
|
Yifeng Pharmacy Chain Co Ltd
SSE:603939
|
Total Equity
¥11.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
|
ShuYu Civilian Pharmacy Corp Ltd
SZSE:301017
|
Total Equity
¥2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Yixintang Pharmaceutical Group Co Ltd
SZSE:002727
|
Total Equity
¥7.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
13%
|
|
|
A
|
Anhui Huaren Health Pharmaceutical Co Ltd
SZSE:301408
|
Total Equity
¥2B
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
DaShenLin Pharmaceutical Group Co Ltd
Glance View
DaShenLin Pharmaceutical Group Co., Ltd. is a fascinating entity woven into the intricate fabric of China's rapidly evolving healthcare landscape. Stemming from humble origins, the company has blossomed into a significant player in the pharmaceutical industry. DaShenLin's business model adeptly combines the traditional with the modern, strategically positioning itself across the supply and distribution spectrum. Primarily, it operates through an extensive retail network, boasting a formidable chain of pharmacies thoughtfully dotted across various provinces. These pharmacies are more than mere outlets; they serve as community health sanctuaries offering an array of pharmaceutical products and health consultations. The company's commitment to traditional Chinese medicine sets it apart, further establishing a niche by fusing age-old healing practices with contemporary medicinal needs. The company's revenue streams are as diverse as its product offerings. Predominantly, it derives income from the direct sale of pharmaceuticals, encompassing both Western drugs and traditional Chinese medicines. Additionally, DaShenLin capitalizes on its robust wholesale operations, providing a steady pipeline of medicinal products to regional hospitals and clinics. The company thrives on its comprehensive supply chain, which ensures an uninterrupted flow of goods from production to consumers' hands. With a keen emphasis on quality and efficacy, DaShenLin continuously invests in research and development, fostering innovation within its product lines. This strategic focus not only reinforces consumer trust but also secures its competitive edge within a dynamic market landscape.
See Also
What is DaShenLin Pharmaceutical Group Co Ltd's Total Equity?
Total Equity
7.2B
CNY
Based on the financial report for Sep 30, 2025, DaShenLin Pharmaceutical Group Co Ltd's Total Equity amounts to 7.2B CNY.
What is DaShenLin Pharmaceutical Group Co Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
8%
Over the last year, the Total Equity growth was 5%. The average annual Total Equity growth rates for DaShenLin Pharmaceutical Group Co Ltd have been 6% over the past three years , 8% over the past five years .